Myeloablative autologous hematopoietic stem cell transplantation resulted in significantly better long-term clinical outcomes—although greater toxicity–in patients with scleroderma than did cyclophosphamide, found a trial published in the New England Journal of Medicine.
The 75 participants with severe scleroderma were randomly assigned to undergo myeloablative autologous stem cell transplantation or to receive cyclophosphamide.
Slomski A. Stem Cell Transplantation Improves Scleroderma Outcomes. JAMA. 2018;319(8):761. doi:10.1001/jama.2018.1204
Customize your JAMA Network experience by selecting one or more topics from the list below.